Art. -Nr.: HY-172209

PPIA-IN-1

Name: PPIA-IN-1
Brand: MedChemExpress
SKU: HY-172209
Price: 300.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Kundenbewertung

Based on 1 Customer Validation

PPIA-IN-1 is a PPIA inhibitor with a K_d value of 0.52 μM. PPIA-IN-1 inhibits the PPIA/MAPK signaling pathway to exert antiproliferative activity. PPIA-IN-1 induces G0/G1 cell cycle arrest in cancer cells. PPIA-IN-1 upregulates the expression of Bax and caspase-3, downregulates Bcl-2 expression, and induces apoptosis in cancer cells. PPIA-IN-1 induces increased ROS levels, DNA damage, endoplasmic reticulum stress, and mitochondrial dysfunction in cancer cells. PPIA-IN-1 exhibits antitumor activity in a mouse colon cancer xenograft model. PPIA-IN-1 can be used for the research of colorectal cancer.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 96.90%
CAS. Nr.: 3077886-94-0
Formel: C₂₃H₂₁Cl₂FN₄O₇
Molecular Weight:555.34

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

PPIA-IN-1 Chemical Structure

CAS. Nr.: 3077886-94-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Alle Caspase Isoform-spezifische Produkte anzeigen :

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

In Vitro

PPIA-IN-1 (Compound 20b) potently inhibits the proliferation of HeLa, HCT116, MCF-7, SW480, CT26, Panc-1 and HepG-2 cells, with IC₅₀ values of 0.69, 0.51, 1.19, 2.59, 0.86, 3.31 and 2.16 μM^[1].
PPIA-IN-1 (0-1.2 μM; 24 h) reduces the colony-forming ability of HCT116 cells and inhibits cell migration and invasion^[1].
PPIA-IN-1 (0-1.2 μM; 48 h) dose-dependently arrests HCT116 cells at the G₀/G₁ phase and downregulates the expression of cyclin A2 and CDK4^[1].
PPIA-IN-1 (0-1.2 μM; 48 h) induces apoptosis in HCT116 cells, upregulates the expression of Bax and caspase-3, and downregulates the expression of Bcl-2 protein^[1].
PPIA-IN-1 (0-1.2 μM; 48 h) increases the intracellular ROS level in HCT116 cells^[1].
PPIA-IN-1 (0-1.2 μM; 48 h) inhibits DNA synthesis and proliferation of HCT116 cells, induces cellular DNA damage, and upregulates the expression of γ-H2AX and p53^[1].
PPIA-IN-1 (0.3-1.2 μM; 48 h) dose-dependently activates endoplasmic reticulum stress and upregulates the expression of PERK, ATF4 and CHOP in HCT116 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[1]

Cell Line:

HCT116 cells
Concentration:

0 μM, 0.3 μM, 0.6 μM, 1.2 μM
Incubation Time:

24 h
Result:

Inhibited scratch wound closure by HCT116 cells in a dose-dependent manner.
Caused significant reductions in migration at all tested concentrations compared to the control group.

Cell Cycle Analysis^[1]

Cell Line:

HCT116 cells
Concentration:

0 μM, 0.3 μM, 0.6 μM, 1.2 μM
Incubation Time:

48 h
Result:

Caused a dose-dependent increase in the percentage of HCT116 cells in the G₀/G₁ phase.
Induced a dose-dependent decrease in the percentage of cells in the S and G₂/M phases.
Downregulated the expression of cell cycle-related proteins cyclin A2 and CDK4 in a dose-dependent manner.

Apoptosis Analysis^[1]

Cell Line:

HCT116 cells
Concentration:

0 μM, 0.3 μM, 0.6 μM, 1.2 μM
Incubation Time:

48 h
Result:

Induced apoptosis in HCT116 cells in a dose-dependent manner, as shown by increased Annexin V-positive cells.
Upregulated the expression of pro-apoptotic proteins Bax and cleaved caspase-3 in a dose-dependent manner.
Downregulated the expression of anti-apoptotic protein Bcl-2 in a dose-dependent manner.

In Vivo

PPIA-IN-1 (15-45 mg/kg; i.p.; once daily; for 14 consecutive days) exhibits potent, dose-dependent antitumor efficacy in the CT26 colon cancer xenograft model of BALB/c mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c (22 g, 3 male and 3 female per group, CT26 colon cancer cells injected subcutaneously to form xenograft tumors)^[1]
Dosage:

15 mg/kg; 45 mg/kg
Administration:

i.p.; daily; 14 days
Result:

Showed significant dose-dependent inhibition of tumor growth compared to the vehicle group.
Reduced tumor weight and volume in a dose-dependent manner, with 45 mg/kg having greater effect than 15 mg/kg.
Caused no significant changes in body weight, unlike 5-FU (HY-90006) and CsA (HY-B0579).
Increased necrosis regions in tumor tissue as revealed by H&E staining.
Caused no obvious injury or abnormality in major organs.
Markedly decreased Ki67 protein levels in tumor tissue.

Related Protocols :

Chemical Information

CAS. Nr. 3077886-94-0
Appearance Solid
Molecular Weight 555.34
Formel C₂₃H₂₁Cl₂FN₄O₇
Color White to off-white
SMILES

O=C(C1(C(OCC)=O)OC(C2=CC=CC=C2F)N3C1N(C(C(OC)=O)=C)C4=NC(Cl)=NC(Cl)=C34)OCC
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (180.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8007 mL

9.0035 mL

18.0070 mL

5 mM

0.3601 mL

1.8007 mL

3.6014 mL

10 mM

0.1801 mL

0.9003 mL

1.8007 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.50 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (289 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Li XJ, et al. Discovery of Novel Oxazolo[4,3-f]purine Derivatives as Antitumor Agents through PPIA Interaction. J Med Chem. 2025;68(5):5573-5596. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8007 mL	9.0035 mL	18.0070 mL	45.0175 mL
	5 mM	0.3601 mL	1.8007 mL	3.6014 mL	9.0035 mL
	10 mM	0.1801 mL	0.9003 mL	1.8007 mL	4.5017 mL
	15 mM	0.1200 mL	0.6002 mL	1.2005 mL	3.0012 mL
	20 mM	0.0900 mL	0.4502 mL	0.9003 mL	2.2509 mL
	25 mM	0.0720 mL	0.3601 mL	0.7203 mL	1.8007 mL
	30 mM	0.0600 mL	0.3001 mL	0.6002 mL	1.5006 mL
	40 mM	0.0450 mL	0.2251 mL	0.4502 mL	1.1254 mL
	50 mM	0.0360 mL	0.1801 mL	0.3601 mL	0.9003 mL
	60 mM	0.0300 mL	0.1501 mL	0.3001 mL	0.7503 mL
	80 mM	0.0225 mL	0.1125 mL	0.2251 mL	0.5627 mL
	100 mM	0.0180 mL	0.0900 mL	0.1801 mL	0.4502 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

PPIA-IN-1

Alle p38 MAPK Isoform-spezifische Produkte anzeigen

Alle Caspase Isoform-spezifische Produkte anzeigen

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen